| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/17/2023 | 27.78% | JP Morgan | $55 → $50 | Maintains | Overweight |
| 09/26/2023 | 53.34% | Citigroup | $60 → $60 | Reiterates | Buy → Buy |
| 09/12/2023 | 27.78% | Baird | → $50 | Initiates Coverage On | → Outperform |
| 08/09/2023 | 22.67% | UBS | $50 → $48 | Maintains | Neutral |
| 02/09/2023 | 32.89% | UBS | $50 → $52 | Maintains | Neutral |
| 02/09/2023 | 53.34% | Citigroup | $55 → $60 | Maintains | Buy |
| 11/09/2022 | 40.56% | Citigroup | $62 → $55 | Maintains | Buy |
| 12/14/2021 | 53.34% | Wells Fargo | $58 → $60 | Maintains | Equal-Weight |
| 10/14/2021 | — | Redburn Partners | Initiates Coverage On | → Buy | |
| 07/14/2021 | 26.58% | Kepler Cheuvreux | → $49.53 | Downgrades | Buy → Hold |
| 06/03/2021 | 32.89% | Goldman Sachs | → $52 | Initiates Coverage On | → Neutral |
| 10/06/2020 | 50.78% | B of A Securities | → $59 | Upgrades | Neutral → Buy |
| 09/28/2020 | 51.6% | Kepler Cheuvreux | → $59.32 | Upgrades | Hold → Buy |
| 08/26/2020 | 68.67% | Commerzbank | → $66 | Upgrades | Hold → Buy |
| 08/24/2020 | 58.45% | Citigroup | $48 → $62 | Upgrades | Neutral → Buy |
| 08/20/2020 | 53.34% | JP Morgan | → $60 | Reinstates | → Overweight |
| 08/14/2020 | — | Exane BNP Paribas | Upgrades | Neutral → Outperform | |
| 08/14/2020 | 53.34% | Deutsche Bank | $32 → $60 | Upgrades | Hold → Buy |
| 04/02/2020 | 2.22% | Stifel | $33 → $40 | Maintains | Hold |
| 03/06/2020 | 7.33% | CFRA | $38 → $42 | Maintains | Hold |
| 02/06/2020 | -2.89% | CFRA | $40 → $38 | Maintains | Hold |
| 01/10/2020 | -8% | UBS | $39 → $36 | Maintains | Neutral |
| 01/08/2020 | -8% | Wells Fargo | → $36 | Initiates Coverage On | → Equal-Weight |
| 01/07/2020 | -10.55% | Citigroup | → $35 | Initiates Coverage On | → Neutral |
| 12/26/2019 | -28.44% | B of A Securities | → $28 | Reinstates | → Underperform |
| 11/18/2019 | 22.67% | Commerzbank | → $48 | Upgrades | Hold → Buy |
| 11/15/2019 | -15.67% | Stifel | → $33 | Initiates Coverage On | → Hold |
| 11/14/2019 | 2.22% | JP Morgan | $25 → $40 | Upgrades | Underweight → Overweight |
| 10/09/2019 | — | Kepler Cheuvreux | Downgrades | Hold → Reduce | |
| 10/08/2019 | -15.67% | B of A Securities | $40 → $33 | Maintains | Neutral |
| 10/08/2019 | -20.78% | Piper Sandler | $36 → $31 | Maintains | Neutral |
| 10/08/2019 | -36.11% | JP Morgan | $38 → $25 | Downgrades | Neutral → Underweight |
| 07/16/2019 | — | Evercore ISI Group | Downgrades | Outperform → In-Line | |
| 03/15/2019 | 7.33% | UBS | → $42 | Initiates Coverage On | → Neutral |
| 10/31/2018 | 4.78% | Morgan Stanley | $39 → $41 | Maintains | Overweight |
What is the target price for Qiagen (QGEN)?
The latest price target for Qiagen (NYSE: QGEN) was reported by JP Morgan on October 17, 2023. The analyst firm set a price target for $50.00 expecting QGEN to rise to within 12 months (a possible 27.78% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Qiagen (QGEN)?
The latest analyst rating for Qiagen (NYSE: QGEN) was provided by JP Morgan, and Qiagen maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Qiagen (QGEN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Qiagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Qiagen was filed on October 17, 2023 so you should expect the next rating to be made available sometime around October 17, 2024.
Is the Analyst Rating Qiagen (QGEN) correct?
While ratings are subjective and will change, the latest Qiagen (QGEN) rating was a maintained with a price target of $55.00 to $50.00. The current price Qiagen (QGEN) is trading at is $39.13, which is out of the analyst's predicted range.